Form 4: Edesa Biotech CEO Pardeep Nijhawan Reports Share Acquisition and Grants Power of Attorney

Pardeep Nijhawan, CEO of Edesa Biotech, reports acquiring 6,392 common shares through a grant of restricted share units and grants power of attorney to Peter J. Weiler for SEC filings.

Summary

• Pardeep Nijhawan, CEO of Edesa Biotech, filed a Form 4 detailing changes in beneficial ownership.
• On May 2, 2025, Nijhawan acquired 6,392 common shares through a grant of restricted share units under the company's 2019 Equity Incentive Compensation Plan.
• These restricted share units vested in full upon grant.
• The reporting person's direct holdings of common shares after the transaction is 178,923.
• Nijhawan also indirectly owns shares through several entities, including Pardeep Nijhawan Medicine Professional Corporation (341,702 shares), The New Nijhawan Family Trust 2015 (32,609 shares), The Digestive Health Clinic Inc. (32,013 shares), and 1968160 Ontario Inc. (53,104 shares).
• Nijhawan disclaims beneficial ownership of shares held by these entities except to the extent of his pecuniary interest.
• Nijhawan granted Peter J. Weiler power of attorney to execute SEC filings on his behalf, effective May 6, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, indicating a neutral sentiment. The acquisition of shares by the CEO could be seen as slightly positive, but it's a routine disclosure.

Positives

• The grant of restricted share units to the CEO could be seen as a positive incentive aligning his interests with those of the shareholders.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in the CEO's ownership stake in the company.

Key Dates

Keywords

Edesa Biotech, EDSA, Pardeep Nijhawan, Form 4, Beneficial Ownership, Restricted Share Units, Power of Attorney, SEC Filing